Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vernalis Hunts For An In-Licensing Deal Or Acquisition In CNS/Oncology

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysts believe Vernalis now is in a "fairly secure" cash position to license or acquire an earlier-stage compound.
Advertisement

Related Content

Vernalis Raises $100 million To Support Push Into U.S. Rx Cough/Cold Market
Business News In Brief
Business News In Brief
Oncology Target Option Deal With GSK Helps Vernalis Hit Comeback Trail

Topics

Advertisement
UsernamePublicRestriction

Register

PS070477

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel